The frequency of gain-of-function in EZH2 demonstrated a higher percentage in ovarian serous cystadenocarcinoma patients (11.4%, 66 cases) than in skin cutaneous melanoma patients (5.7%, 21 cases). This evidence concerns the gene EZH2 and cutaneous melanoma.